phase 1_2_completion
saveAstraZeneca Plc — Calquence (Phase I/II Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: CNS Lymphoma, Diffuse Large B-Cell Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma
Data sources
globaldata
Found something off?
drug timeline · 8
- approvalCALQUENCE (ACALABRUTINIB) — FDA approvalFeb 19, 2026 · 234d ago
- approvalCALQUENCE (ACALABRUTINIB MALEATE) — FDA approvalFeb 19, 2026 · 234d ago
- approvalCALQUENCE (ACALABRUTINIB) — FDA approvalJan 16, 2025 · 633d ago
- approvalCALQUENCE (ACALABRUTINIB MALEATE) — FDA approvalJan 16, 2025 · 633d ago
- approvalCALQUENCE (ACALABRUTINIB) — FDA approvalJun 5, 2024 · 858d ago
- approvalCALQUENCE (ACALABRUTINIB MALEATE) — FDA approvalJun 5, 2024 · 858d ago
- approvalCALQUENCE (ACALABRUTINIB MALEATE) — FDA approvalAug 3, 2022 · 1530d ago
- approvalCALQUENCE (ACALABRUTINIB MALEATE) — FDA approvalAug 3, 2022 · 1530d ago
same company · ±60 days · 6
- fda advisory committee meetingcapivasertib: AstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)Apr 30, 2026
- fda advisory committee meetingcamizestrant: AstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)Apr 30, 2026
- phase 2 completiontozorakimab: AstraZeneca Plc — tozorakimab (Phase II Trial Completion)Apr 30, 2026
- phase 3 completiondurvalumab: AstraZeneca Plc — durvalumab (Phase III Trial Completion)Apr 29, 2026
- earningsASTRAZENECA PLC earningsApr 29, 2026
- approvaleplontersen sodium: WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approvalApr 15, 2026
comments(0)
5-min edit window · permanent after that